 Home > Active Ingredient News > Study of Nervous System > Neurology: Long-term efficacy of ponimod in the treatment of relapsing-remitting multiple sclerosis

Neurology: Long-term efficacy of ponimod in the treatment of relapsing-remitting multiple sclerosis

 Last Update: 2022-09-06
 Source: Internet
 Author: User

Tags

concerta 36 mg

1 4 npt

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A recent study published in the journal Neurology assessed the dose-response relationship and wavelet of 10, 20, and 40 mg of ponimod using a combined data analysis of the Phase 2 core and extension studies in patients with relapsing multiple sclerosis (RRMS).

In the core study, 464 patients were randomly assigned (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n = 116), or 40 mg of ponimod (n = 119), once daily for 24 weeks

A total of 435 patients received ≥1 dose of ponimod (first randomized dose: 10mg=139, 20mg=145, and 40mg=151)

In conclusion, the control effect of Ponimod 20mg on multiple sclerosis was maintained for about 8 years, and no new safety issues were found

references:

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis Results From Randomized Phase 2b Core and Extension Studies.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.